2023
Achieving Value by Risk Stratification With Machine Learning Model or Clinical Risk Score in Acute Upper Gastrointestinal Bleeding: A Cost Minimization Analysis
Shung D, Lin J, Laine L. Achieving Value by Risk Stratification With Machine Learning Model or Clinical Risk Score in Acute Upper Gastrointestinal Bleeding: A Cost Minimization Analysis. The American Journal Of Gastroenterology 2023, 119: 371-373. PMID: 37753930, PMCID: PMC10872988, DOI: 10.14309/ajg.0000000000002520.Peer-Reviewed Original ResearchUpper gastrointestinal bleedingCost-minimization analysisGastrointestinal bleedingUsual careTriage strategiesAcute upper gastrointestinal bleedingClinical risk scoreLow-risk patientsHealthcare payer perspectiveMinimization analysisRisk assessment toolRisk stratificationEmergency departmentPayer perspectiveRisk scoreBleedingAssessment toolCareRisk assessment modelMachine-learning strategiesPatientsCumulative savingsCost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma
Potnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.Peer-Reviewed Original ResearchConceptsCAR T-cell therapyT-cell therapyQuality-adjusted life yearsIncremental cost-effectiveness ratioCAR T cellsChimeric antigen receptor T-cell therapySOC therapyFollicular lymphomaT cellsLife yearsR FLRefractory follicular lymphomaT cell strategiesThird-line settingLines of therapyIncremental clinical benefitUS payer perspectiveCost-effectiveness ratioTherapy remissionUnselected patientsCare therapyClinical benefitClinical trialsTreatment strategiesPayer perspective
2022
Treatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factor
2021
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma
Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2021, 62: 2777-2784. PMID: 34151696, DOI: 10.1080/10428194.2021.1933477.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioRefractory multiple myelomaMultiple myelomaWeekly selinexorR Multiple MyelomaProgression-free survivalUS payer perspectiveCost-effectiveness ratioWeekly bortezomibTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessBortezomibIncremental costMyelomaDexamethasoneSelinexorQALYVDPatientsCost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.
Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.Peer-Reviewed Original ResearchConceptsTransplant-ineligible patientsIncremental cost-effectiveness ratioFirst-line settingHealthcare costsClinical outcomesMultiple myelomaProgression-free survivalOverall survival dataUS payer perspectiveDirect healthcare costsCost-effectiveness ratioRandomized trialsDisease progressionTreatment strategiesParametric survival modelingPayer perspectiveSubsequent linesLater linesPatientsCostly treatmentIncremental costQALYSurvival dataLenalidomideMyeloma
2020
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioHealth care costsFirst-line ibrutinibLifetime direct health care costsCare costsCost-effectiveness ratioParametric survival modelingUnselected older adultsDirect health care costsUS payer perspectiveCurrent pricingLife yearsFixed-duration treatmentIncremental costIncremental effectivenessPayer perspectiveHigher health care costsIbrutinib armScenario analysisMonthly costCostPricingChronic lymphocytic leukemiaMarkov modelCost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma
Patel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioLarge B-cell lymphomaB-cell lymphomaPola-BRR DLBCLRefractory diffuse large B-cell lymphomaLonger progression-free survivalRecent phase II trialDiffuse large B-cell lymphomaProgression-free survivalTransplant-ineligible patientsPhase II trialUS payer perspectiveCost-effectiveness ratioII trialOverall survivalTreatment strategiesPayer perspectiveLifetime horizonIncremental effectivenessIncremental costPolatuzumabRituximabLymphomaDLBCL
2019
Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3 mut+) Acute Myeloid Leukemia (AML)
Zeidan A, Qi C, Pandya B, Garnham A, Yang H, Shah M. Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3 mut+) Acute Myeloid Leukemia (AML). Blood 2019, 134: 3859. DOI: 10.1182/blood-2019-123819.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationEvent-free survivalAcute myeloid leukemiaIncremental cost-effectiveness ratioUS third-party payer perspectiveThird-party payer perspectiveProbabilistic sensitivity analysesSalvage chemotherapyADMIRAL trialOverall survivalEfficacy inputsDeterministic sensitivity analysesIncremental costPayer perspectiveLifetime horizonAllogeneic hematopoietic stem cell transplantationFavorable cost-effectiveness profileHealth statesPost-progression treatmentTerminal care costsTreatment of RelapsedActive treatment optionsEffective therapeutic optionLong-term survivorsTreatment costsCost-minimization study of the percutaneous approach to endovascular aortic aneurysm repair
Hong JC, Yang GK, Delarmente BA, Khera R, Price J, Faulds J, Chen JC. Cost-minimization study of the percutaneous approach to endovascular aortic aneurysm repair. Journal Of Vascular Surgery 2019, 71: 444-449. PMID: 31176637, DOI: 10.1016/j.jvs.2019.03.040.Peer-Reviewed Original ResearchConceptsEndovascular aortic aneurysm repairVascular closure deviceAortic aneurysm repairLength of hospitalizationP-EVARCost savingsProbabilistic sensitivity analysesAneurysm repairSensitivity analysisTwo-way sensitivity analysesCost-minimization studyCost saving strategyEconomic effectsCost parametersMean cost savingsCost differencesPayer perspectiveSurgical site infectionNational Inpatient SampleThoracic EVARResource allocationSaving strategiesBase caseSavingsSummary measuresPersistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014
Yu JB, Pollack CE, Herrin J, Zhu W, Soulos PR, Xu X, Gross CP. Persistent Use of Extended Fractionation Palliative Radiotherapy for Medicare Beneficiaries With Metastatic Breast Cancer, 2011 to 2014. American Journal Of Clinical Oncology 2019, 42: 493-499. PMID: 31033511, PMCID: PMC6538429, DOI: 10.1097/coc.0000000000000548.Peer-Reviewed Original ResearchConceptsPalliative radiotherapyBone metastasesMedicare beneficiariesBreast cancerAssociation of clinicalProportion of patientsChoice of treatmentHospital-based practiceService Medicare beneficiariesSingle-fraction treatmentProvider financial incentivesLogistic regression modelsDifferent fractionation schemesProlonged courseRadiation courseRadiotherapy usePayer perspectiveProvider characteristicsMean costMultiple guidelinesPatientsRadiotherapyMetastasisCancerNumber of daysExamining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy
Abu-Khalaf MM, Safonov A, Stratton J, Wang S, Hatzis C, Park E, Pusztai L, Gross CP, Russell R. Examining the cost-effectiveness of baseline left ventricular function assessment among breast cancer patients undergoing anthracycline-based therapy. Breast Cancer Research And Treatment 2019, 176: 261-270. PMID: 31020471, DOI: 10.1007/s10549-019-05178-z.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEquilibrium radionuclide angiographyCardiac risk factorsBreast cancer patientsVentricular function assessmentRisk factorsAbnormal LVEFBaseline LVEFCancer patientsBreast cancerFunction assessmentPotential cardiac risk factorsSelf-reported risk factorsAnthracycline-based therapyLeft ventricular function assessmentCoronary artery diseaseCost-effectiveness ratioArtery diseaseTrastuzumab therapyCardiac screeningPatient populationRadionuclide angiographyCardiotoxicity riskPayer perspectiveRetrospective analysis
2018
Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma
Huntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal Of Clinical Oncology 2018, 36: jco.18.00122. PMID: 30285558, PMCID: PMC6241679, DOI: 10.1200/jco.18.00122.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioFirst-line settingFirst-line therapyBrentuximab vedotinHodgkin's lymphomaHealth care costsStage IIICare costsDirect health care costsLifetime health care costsOpen-label trialCohort of patientsRisk of progressionUS payer perspectiveMarkov decision-analytic modelCost-effectiveness ratioDecision analytic modelFavourable cost effectivenessCost-effectiveness analysisStandard ABVDClinical outcomesPayer perspectiveParametric survival distributionsIndication-specific pricingCost effectiveness
2017
Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST)
Patrice G, Lester-Coll N, Yu J, Amdahl J, Delea T, Patrice S. Cost-Effectiveness of Thoracic Radiation Therapy for Extensive-Stage Small Cell Lung Cancer Using Evidence From the Chest Radiotherapy Extensive-Stage Small Cell Lung Cancer Trial (CREST). International Journal Of Radiation Oncology • Biology • Physics 2017, 100: 97-106. PMID: 29029885, DOI: 10.1016/j.ijrobp.2017.08.041.Peer-Reviewed Original ResearchConceptsExtensive-stage small cell lung cancerThoracic radiation therapyProgression-free survivalIncremental cost-effectiveness ratioExtensive-stage small cell lung cancer patientsSmall cell lung cancerCell lung cancerStandard treatmentLung cancer trialsRadiation therapyOverall survivalLung cancerUS health care payer perspectiveLong-term survival benefitCancer trialsFavorable incremental cost-effectiveness ratiosProgressive metastatic diseaseHealth care payer perspectiveProportion of patientsBase-case analysisFollow-up intervalCost-effectiveness ratioMetastatic diseasePostprogression survivalPayer perspectiveCost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure
Dang W, Yi A, Jhamnani S, Wang SY. Cost-Effectiveness of Multidisciplinary Management Program and Exercise Training Program in Heart Failure. The American Journal Of Cardiology 2017, 120: 1338-1343. PMID: 28842145, DOI: 10.1016/j.amjcard.2017.06.071.Peer-Reviewed Original ResearchConceptsMultidisciplinary management programIncremental cost-effectiveness ratioUsual careLife yearsHeart failureExercise training programHealthcare payer perspectiveCost-effectiveness ratioProbabilistic sensitivity analysesCost-effectiveness thresholdCurrent cost-effectiveness thresholdsPayer perspectiveHealthcare costsHealth outcomesTraining programSocietal perspectiveSignificant healthFinancial burdenPatientsManagement programETPFailureYearsCareCost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings
Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine 2017, 35: 3506-3514. PMID: 28527687, PMCID: PMC5462484, DOI: 10.1016/j.vaccine.2017.05.001.Peer-Reviewed Original ResearchConceptsRoutine infant vaccinationCost-effectiveness analysisOptimal strategyHealthcare payer perspectiveVaccine priceOne-time catchMiddle-income countriesIntervention costsPayer perspectiveInfant vaccinationDong ThapRoutine vaccinationMiddle-income settingsTyphoid transmissionRate of hospitalizationNumber of dosesDynamic modelPricesWorld Health OrganizationInvestmentLwakReturnWillingnessTyphoid feverVaccinationCost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis
Berger BA, Cossio A, Saravia NG, del Mar Castro M, Prada S, Bartlett AH, Pho MT. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis. PLOS Neglected Tropical Diseases 2017, 11: e0005459. PMID: 28384261, PMCID: PMC5404883, DOI: 10.1371/journal.pntd.0005459.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAntiprotozoal AgentsCaregiversChildChild, PreschoolCost-Benefit AnalysisDirectly Observed TherapyDrug CostsFemaleHumansInjections, IntramuscularLeishmaniaLeishmaniasis, CutaneousMaleMeglumineMeglumine AntimoniateMonte Carlo MethodOrganometallic CompoundsPhosphorylcholineSensitivity and SpecificityTreatment OutcomeUnited StatesConceptsPediatric cutaneous leishmaniasisMeglumine antimoniateCutaneous leishmaniasisGovernment payer perspectivePayer perspectivePatient's perspectiveMean differenceSocietal perspectiveCost-effectiveness analysisSurvey of providersOral miltefosineAdverse eventsObserved therapyPrimary outcomeHealthcare utilizationClinical trialsMean costTreatment efficacyDrug effectivenessMiltefosineHome caregiversSocietal costsLeishmaniasisCureTreatment
2015
Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis
Malhotra A, Wu X, Kalra VB, Schindler J, Matouk CC, Forman HP. Evaluation for Blunt Cerebrovascular Injury: Review of the Literature and a Cost-Effectiveness Analysis. American Journal Of Neuroradiology 2015, 37: 330-335. PMID: 26450540, PMCID: PMC7959958, DOI: 10.3174/ajnr.a4515.Peer-Reviewed Original ResearchConceptsCost-effective imaging strategyNet monetary benefitHealth care payer perspectiveIncremental cost-effectiveness ratioCare payer perspectiveCost-effectiveness analysisCost-effective strategyCost-effectiveness ratioEconomic evaluationMonetary benefitsDominant strategyMain indicatorsPayer perspectiveSelective DSAComparable utilityUtility perspectiveDecision tree analysisSelective anticoagulationSensitivity analysisCostImmense controversyHigh costCTA sensitivityParameter valuesHorizon
2014
Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument
Jayakrishnan T, Nadeem H, Groeschl R, George B, Thomas J, Ritch P, Christians K, Tsai S, Evans D, Pappas S, Gamblin T, Turaga K. Diagnostic laparoscopy should be performed before definitive resection for pancreatic cancer: a financial argument. Hepato Pancreato Biliary 2014, 17: 131-139. PMID: 25123702, PMCID: PMC4299387, DOI: 10.1111/hpb.12325.Peer-Reviewed Original ResearchConceptsQuality-adjusted life monthsNeoadjuvant therapy patientsNeoadjuvant therapyDiagnostic laparoscopyCurative resectionIncremental cost-effectiveness ratioPancreatic cancerTime of curative resectionRadiographically occult metastasesPancreatic cancer patientsMulti-way sensitivity analysesCost-effectiveness ratioDefinitive resectionOccult metastasesSF patientsExploratory laparotomyLife monthsResectionCancer patientsPayer perspectiveLaparoscopyPatientsTreatment typeBase case costCost-effective
2013
National cost of trauma care by payer status
Velopulos C, Enwerem N, Obirieze A, Hui X, Hashmi Z, Scott V, Cornwell E, Schneider E, Haider A. National cost of trauma care by payer status. Journal Of Surgical Research 2013, 184: 444-449. PMID: 23800441, PMCID: PMC5995319, DOI: 10.1016/j.jss.2013.05.068.Peer-Reviewed Original ResearchConceptsPayer statusTrauma carePrivate insuranceNationwide Inpatient SamplePatient case mixUS dollar equivalentsPatient characteristicsNinth RevisionPresent studyInpatient costsHospital characteristicsInpatient SampleClinical ModificationTraumatic injuryPayer perspectiveRetrospective analysisSample patientsInternational ClassificationType of insuranceEconomic burdenCase mixPatientsNational population estimatesTrauma costTeaching status
2009
Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal
Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, Walensky RP, Messou E, Weinstein MC, Dabis F, Freedberg KA, AIDS F, investigators A. Cost-Effectiveness of Preventing Loss to Follow-up in HIV Treatment Programs: A Côte d'Ivoire Appraisal. PLOS Medicine 2009, 6: e1000173. PMID: 19859538, PMCID: PMC2762030, DOI: 10.1371/journal.pmed.1000173.Peer-Reviewed Original ResearchConceptsHIV treatment programsResource-limited settingsPerson/yearART initiationAIDS Complications-International modelTreatment programWorld Health Organization criteriaAntiretroviral therapy initiationLTFU ratesHIV careTherapy initiationCumulative incidenceClinical benefitOrganization criteriaClinical impactLTFUPayer perspectiveCost of interventionInternational criteriaLife expectancyEfficacyInterventionPreventing LossCareSurvival loss
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply